CRISPR-associated (Cas) proteins with reduced immunogenicity
AssigneeLonza Ltd.
InventorsThomas Payne, Jesús Zurdo, Noel Hillier Smith
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of reducing the immunogenicity of CRISPR-associated (Cas) proteins and the modified Cas proteins produced therefrom. In addition, the invention relates to methods for cell and gene therapy, including any and all genetic modifications and alterations of gene expression (and/or genetic elements) made in-vivo or ex-vivo using Cas proteins with reduced immunogenicity.
Claims7
A method for reducing the immunogenicity of a CRISPR-associated 9 (Cas9) protein, the method comprising introducing one or more amino acid substitutions into one or more residues corresponding to one or more major histocompatibility (MHC) Class I and/or Class II binding sites of the Cas9 protein to form a recombinant Cas9 protein;
- wherein the amino acid sequence of the Cas9 protein is at least 95% identical to full-length SEQ ID NO:5;
- and
- wherein the one or more amino acid substitutions are one or more of:
- L106D, K263D, L696G, L847D, or I1281D.
A recombinant CRISPR-associated 9 (Cas9) protein made by a method comprising introducing one or more amino acid substitutions into one or more residues corresponding to one or more major histocompatibility (MHC) Class I and/or Class II binding sites of the Cas9 protein to form the recombinant Cas9 protein;
- wherein the amino acid sequence of the Cas9 protein is at least 95% identical to full-length SEQ ID NO:5;
- and
- wherein the one or more amino acid substitutions are one or more of:
- L106D, K263D, L696G, L847D, or I1281D.
Dependencies are inferred from the claim text.